TY - JOUR T1 - Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Charles JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e110 LP - e110 DO - 10.1136/annrheumdis-2021-220164 VL - 82 IS - 5 AU - Josef S Smolen Y1 - 2023/05/01 UR - http://ard.bmj.com/content/82/5/e110.abstract N2 - In his correspondence, Charles challenged the appropriateness of publishing the COVID High-intensity Immunosuppression in Cytokine storm syndrome (CHIC) study in ARD.1 2 I am always grateful for our readers’ critical assessments of papers published in ARD, since this allows the authors to address further questions of interest and thus provide additional clarification. Ramiro et al have done so in their response to Charles’ critique.3Regarding the decision to publish the paper, I can assure Charles that all research papers in ARD undergo a full peer-review process. In this case, the paper was reviewed by three top experts in the field who all regarded it as an important contribution and recommended publication after revision. … ER -